KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EBITDA (2016 - 2025)

Historic EBITDA for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.

  • Amgen's EBITDA rose 2340.01% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 billion, marking a year-over-year increase of 3945.0%. This contributed to the annual value of $7.3 billion for FY2024, which is 809.17% down from last year.
  • Per Amgen's latest filing, its EBITDA stood at $2.5 billion for Q3 2025, which was up 2340.01% from $2.7 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's EBITDA registered a high of $2.7 billion during Q2 2023, and its lowest value of $828.0 million during Q2 2021.
  • For the 5-year period, Amgen's EBITDA averaged around $2.0 billion, with its median value being $2.2 billion (2022).
  • Per our database at Business Quant, Amgen's EBITDA crashed by 6435.64% in 2021 and then surged by 16280.19% in 2022.
  • Amgen's EBITDA (Quarter) stood at $2.3 billion in 2021, then fell by 3.21% to $2.2 billion in 2022, then plummeted by 43.0% to $1.3 billion in 2023, then soared by 81.83% to $2.3 billion in 2024, then grew by 9.3% to $2.5 billion in 2025.
  • Its EBITDA stands at $2.5 billion for Q3 2025, versus $2.7 billion for Q2 2025 and $1.2 billion for Q1 2025.